Detailed price information for Solid Biosciences Inc (SLDB-Q) from The Globe and Mail including charting and trades.
A cutting-edge therapy using base-edited immune cells is offering a major breakthrough for patients with one of the toughest ...
From rare diseases to chronic conditions, epigenetic editing unlocks new ways to control gene activity without altering the genetic code.
For men with hemophilia B, receipt of gene therapy comprising an infusion of etranacogene dezaparvovec results in sustained endogenous factor IX expression and low annualized bleeding rates over five ...
The Food and Drug Administration this week granted approval to a new gene therapy for a rare immune disorder, the maker of which is notably not a drug ...
A breakthrough therapy is driving aggressive leukaemia into remission. Here’s what the headlines don’t tell you about life ...
Backed by Italy-based Fondazione Telethon ETS, Waskyra, for Wiskott-Aldrich syndrome, is the first gene therapy from a ...
EpilepsyGTx, a biotechnology company focused on research and development of cutting-edge gene therapies to treat refractory epilepsy, today announced it has raised $33 million in a Series A financing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback